Commentary: Wayne Fenton's impact on industry

被引:1
作者
Breier, Alan [1 ]
Alphs, Larry
Binneman, Brendon
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Pfizer Inc, Cent Nervous Syst Clin Dev, New York, NY 10017 USA
[3] Pfizer Inc, Clin Res & Dev, New York, NY 10017 USA
关键词
schizophrenia; cognition; negative symptoms;
D O I
10.1093/schbul/sbm068
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
引用
收藏
页码:1154 / 1155
页数:2
相关论文
共 2 条
[1]   A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. [J].
Buchanan, RW ;
Davis, M ;
Goff, D ;
Green, MF ;
Keefe, RSE ;
Leon, AC ;
Nuechterlein, KH ;
Laughren, T ;
Levin, R ;
Stover, E ;
Fenton, W ;
Marder, SR .
SCHIZOPHRENIA BULLETIN, 2005, 31 (01) :5-19
[2]   The NIMH-MATRICS consensus statement on negative symptoms [J].
Kirkpatrick, B ;
Fenton, WS ;
Carpenter, WT ;
Marder, SR .
SCHIZOPHRENIA BULLETIN, 2006, 32 (02) :214-219